Used primarily in chemotherapy for treating various cancers, especially non-small cell lung cancer and head and neck cancers. It functions by cross-linking DNA, which inhibits DNA replication and transcription, leading to cancer cell death. Nedaplatin is often preferred in patients who have developed resistance to or cannot tolerate cisplatin due to its relatively lower nephrotoxicity. It is administered intravenously and commonly used in combination with other anticancer agents to enhance therapeutic efficacy. Its application is particularly notable in Japan and parts of Asia, where it is approved and widely integrated into clinical oncology practice.